Skip to content

William E Fantegrossi

33 papers in the library · 662 citations · publishing 2004-2026

Papers

Sort Most recent Most cited

Effects of Psychedelics Lysergic Acid Diethylamide and R (–)-2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Consumption and Naloxone-Precipitated Withdrawal in Male C57Bl/6J Mice

Psychedelic Medicine March 28, 2026 Levi Neal, Hannah E. Shaw, Brenda M. Gannon et al.

Background: There are currently three FDA-approved medications for opioid use disorder (OUD), but none of them are especially effective, some can precipitate withdrawal in dependent individuals, and all of them require daily administration. In the appropriate settings, single administrations of psychedelics can elicit persistent anti-addiction effects in humans and in laboratory animals, but...

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Journal of Psychopharmacology 2026 Jack E Henningfield, Sandra D Comer, Matthew L Banks et al. 5 citations

Abuse potential assessment of drugs with central nervous system activity is a critical component of the development of new medications for regulatory filings for approval worldwide. These new drug applications typically include recommendations for scheduling status as a controlled substance, if scheduling is warranted. This commentary focuses on the approach and current issues related to...

Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents

Journal of Pharmacology and Experimental Therapeutics January 25, 2024 Hannah E. Shaw, D. R. Patel, Brenda M. Gannon et al.

Abuse of novel arylcyclohexylamines (ACX) poses risks for toxicities, including adverse neurocognitive effects. In vivo effects of ring-substituted analogs of phencyclidine (PCP), eticyclidine (PCE), and ketamine are understudied. Adult male National Institutes of Health Swiss mice were used to assess locomotor effects of PCP and its 3-OH, 3-MeO, 3-Cl, and 4-MeO analogs, PCE and its 3-OH and...

Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.

Psychedelic Medicine September 1, 2023 Harpreet Kaur, Sedat Karabulut, James W Gauld et al. 10 citations

Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication and social interaction and repetitive, inflexible patterns of behaviors, interests, and thoughts. ASD affects people worldwide, irrespective of race, ethnicity, or socio-economic status, with debilitating effects on employment and interpersonal...

Effects of ambient temperature on locomotor activity and place conditioning elicited by abused psychostimulants in mice: Role of 3,4-methylenedioxy moiety.

Drug and Alcohol Dependence September 1, 2023 Brenda M. Gannon, Lauren R Fitzgerald, Christopher O Godwin et al.

Humans often administer psychostimulants in party or music festival settings characterized by warm ambient temperatures, which may impact drug effects; however, preclinical studies rarely investigate drug effects at multiple ambient temperatures. Work with 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) suggests that the presence of a 3,4-methylenedioxy ring...

DOI: 10.1016/j.drugalcdep.2023.110917 (opens in new tab) Full text (opens in new tab) Ambient temperature Cathinones Conditioned place preference Locomotor activity +2

Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.

Toxicological sciences : an official journal of the Society of Toxicology April 26, 2022 Christian V Cabanlong, Lauren N Russell, William E Fantegrossi et al.

Synthetic cannabinoid receptor agonists (SCRAs) are a large group of abused psychoactive compounds that elicit numerous toxic effects not observed with cannabis, including death. Abuse of third-generation SCRA 5F-MDMB-PINACA (also known as 5F-ADB) has been associated with over 40 fatalities. This SCRA is metabolized to several active phase I metabolites, including excessively high post-mortem...

DOI: 10.1093/toxsci/kfac024 (opens in new tab) Full text (opens in new tab) G-protein coupled receptors Cb1 receptors Metabolites Novel psychoactive substances +2

Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) on alcohol consumption in Long-Evans rats

Behavioural Pharmacology February 15, 2021 Michael D. Berquist, William E Fantegrossi

Supplemental Digital Content is available in the text. The objectives of this study were to determine alcohol consumption after administration of (R)(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) or naltrexone in Long–Evans rats, and to assess the effectiveness of these treatments based on individual differences in alcohol consumption. Adult male Long–Evans rats (N = 16) were given opportunities to...

In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation.

Drug and Alcohol Dependence January 13, 2020 Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.

BACKGROUND Recent clinical studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct treatment for posttraumatic stress disorder (PTSD). Despite these promising findings, MDMA administration in controlled settings can increase blood pressure, heart rate, and body temperature. Previous studies indicate thatO-demethylated metabolites of MDMA contribute to its adverse...

Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization

Psychopharmacology November 15, 2019 Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.

There is a renewed interest in the use of 3,4-methylenedioxymethamphetamine (MDMA) for treating psychiatric conditions. Although MDMA has entered phase II clinical trials and shows promise as an adjunct treatment, there is an extensive literature detailing the potential neurotoxicity and adverse neurobehavioral effects associated with MDMA use. Previous research indicates that the adverse...

Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018.

Journal of Pharmacology and Experimental Therapeutics May 2019 Benjamin M Ford, Christian V Cabanlong, Sherrica Tai et al.

Most cannabinoid 1 receptor (CB1R) agonists will signal through both G protein-dependent and -independent pathways in an unbiased manner. Recruitment of β-arrestin 2 desensitizes and internalizes receptors, producing tolerance that limits therapeutic utility of cannabinoids for chronic conditions. We developed the indole quinuclidinone (IQD) analog...

Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants.

Biochemical and Biophysical Research Communications April 6, 2018 Amy L Patton, Kathryn A Seely, Azure L Yarbrough et al.

Synthetic cannabinoids (SCBs), synonymous with 'K2', 'Spice' or 'synthetic marijuana', are psychoactive drugs of abuse that frequently result in clinical effects and toxicity more severe than those classically associated with Δ9-tetrahydrocannabinol such as extreme agitation, hallucinations, supraventricular tachycardia, syncope, and seizures. JWH-018 is one of the earliest compounds identified...

DOI: 10.1016/j.bbrc.2018.03.028 (opens in new tab) Full text (opens in new tab) Cyp2c9 variants Cyp450 Enzyme kinetics Synthetic cannabinoids +1

Phencyclidine-like in vivo effects of methoxetamine in mice and rats

Neuropharmacology August 19, 2017 Michael D. Berquist, William S Hyatt, Jonathan J. Bauer-Erickson et al.

Methoxetamine (MXE) is a novel drug of abuse that is structurally similar to phencyclidine (PCP). In the present study, rats were trained to discriminate PCP from saline and substitution tests were performed with arylcyclohexylamines PCP, eticyclidine (PCE), tenocyclidine (TCP), and MXE. PCP and PCE engendered PCP-lever selection in all subjects, whereas MXE and TCP produced PCP-lever selection...

Effects of serotonergic hallucinogen R (−)‐2,5‐Dimethoxy‐4‐iodoamphetamine (DOI) on temporal discrimination in mice

The FASEB Journal April 1, 2017 Michael P Trahan, Sebastian Leth-Petersen, William E Fantegrossi

R (−)‐2,5‐Dimethoxy‐4‐iodoamphetamine (DOI) and other compounds with agonist affinity for serotonergic 5‐HT2A receptors are hallucinogenic drugs of abuse, but also have therapeutic potential in numerous neuropsychiatric conditions, including major depressive disorder, post‐traumatic stress disorder, and in the treatment of migraine and cluster headaches. Thus, commonly abused hallucinogens...

Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites

Current Topics in Behavioral Neurosciences 2017 S. Tai, William E Fantegrossi

Commercial preparations containing synthetic cannabinoids (SCBs) are rapidly emerging as drugs of abuse. Although often assumed to be “safe” and “legal” alternatives to cannabis, reports indicate that SCBs induce toxicity not often associated with the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). This chapter will summarize the evidence that use of SCBs poses...

Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells

Neuroscience Letters June 16, 2016 H. Rosas-Hernández, Elvis Cuevas, Susan M. Lantz et al.

Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. In addition to methamphetamine (METH), these drugs include 3,4- methylenedioxy-methamphetamine (MDMA) and commercial preparations of synthetic cathinones including 3,4-methylenedioxypyrovalerone (MDPV), typically referred to as “bath salts.” These psychostimulants exert...

Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Pharmacological Research December 2015 S Tai, William S Hyatt, C Gu et al.

These studies probed the relationship between intrinsic efficacy and tolerance/cross-tolerance between ∆(9)-THC and synthetic cannabinoid drugs of abuse (SCBs) by examining in vivo effects and cellular changes concomitant with their repeated administration in mice. Dose-effect relationships for hypothermic effects were determined in order to confirm that SCBs JWH-018 and JWH-073 are higher...

DOI: 10.1016/j.phrs.2015.09.006 (opens in new tab) Full text (opens in new tab) Cb1r Cannabinoid Cross-tolerance Desensitization +1

Effects of 3,4‐Methylenedioxypyrovalerone (MDPV) and 3,4‐Methylenedioxymethamphetamine (MDMA) on Place Conditioning in Mice

The FASEB Journal April 1, 2015 Brenda M. Gannon, Julia Tobacyk, William E Fantegrossi

Recently, there has been an increase in abuse of new synthetic psychostimulant drugs derived from the cathinone structure. These products are typically referred to as “bath salts”, and one of the most common psychoactive constituents of these preparations is 3,4‐methylenedioxypyrovalerone (MDPV). In these studies, we used the conditioned place preference (CPP) paradigm to explore the apparent...

Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.

Journal of Pharmacology and Experimental Therapeutics December 1, 2014 Douglas A Smith, Jessica M Bailey, Diarria Williams et al. 31 citations

The serotonin 5-hydroxytryptamine 2A (5-HT2A) receptor is a potential therapeutic target to a host of neuropsychiatric conditions, but agonist actions at this site are linked to abuse-related hallucinogenic effects that may limit therapeutic efficacy of chronic drug administration. Tolerance to some effects of hallucinogens has been observed in humans and laboratory animals, but the...

DOI: 10.1124/jpet.114.219337 (opens in new tab) Full text (opens in new tab) Drug tolerance Drug adaptation Pharmacological tolerance Reduced drug effectiveness +15

Baths Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines

Journal of Neuroscience November 12, 2014 Michael H. Baumann, Ernesto Solis, Lucas R. Watterson et al. 157 citations

The abuse of synthetic psychoactive substances known as "designer drugs," or "new psychoactive substances" (NPS), is increasing at an alarming rate. NPS are purchased as alternatives to traditional illicit drugs of abuse and are manufactured to circumvent laws regulating the sale and use of controlled substances. Synthetic cathinones (i.e., "bath salts") and synthetic cannabinoids (i.e.,...

DOI: 10.1523/jneurosci.3223-14.2014 (opens in new tab) Full text (opens in new tab) MDMA Synthetic cannabinoids Designer drug Recreational drug +4

Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice.

Behavioural Pharmacology June 2014 William S Hyatt, William E Fantegrossi

The emergence of high-efficacy synthetic cannabinoids as drugs of abuse in readily available K2/'Spice' smoking blends has exposed users to much more potent and effective substances than the phytocannabinoids present in cannabis. Increasing reports of adverse reactions, including dependence and withdrawal, are appearing in the clinical literature. Here we investigated whether the effects of one...

Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Journal of Pharmacology and Experimental Therapeutics September 2013 Lisa K Brents, Sarah M Zimmerman, Amanda R Saffell et al.

Marijuana substitutes often contain blends of multiple psychoactive synthetic cannabinoids (SCBs), including the prevalent SCBs (1-pentyl-1H-indole-3-yl)-1-naphthalenyl-methanone (JWH-018) and (1-butyl-1H-indole-3-yl)-1-naphthalenyl-methanone (JWH-073). Because SCBs are frequently used in combinations, we hypothesized that coadministering multiple SCBs induces synergistic drug-drug...

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.

PLoS One 2011 Lisa K Brents, Emily E Reichard, Sarah M Zimmerman et al.

K2 products are synthetic cannabinoid-laced, marijuana-like drugs of abuse, use of which is often associated with clinical symptoms atypical of marijuana use, including hypertension, agitation, hallucinations, psychosis, seizures and panic attacks. JWH-018, a prevalent K2 synthetic cannabinoid, is structurally distinct from Δ(9)-THC, the main psychoactive ingredient in marijuana. Since even...

Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys.

Psychopharmacology May 2010 Jessica McClung, William E Fantegrossi, Leonard L. Howell

The effectiveness of MDMA and its enantiomers to reinstate responding previously maintained by drug self-administration has not been thoroughly investigated. The present study was designed to compare the reinstatement effects of amphetamine, the piperazine-analog BZP, SR(+/-)-MDMA, S(+)-MDMA, R(-)-MDMA, and fenfluramine on behavior maintained under a second-order schedule of intravenous...

Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice.

Journal of Pharmacology and Experimental Therapeutics November 1, 2009 Kevin S. Murnane, Naoki Murai, Leonard L. Howell et al. 34 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two...

Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations.

Journal of Pharmacology and Experimental Therapeutics June 2009 William E Fantegrossi, Naoki Murai, Brian O Mathúna et al.

3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse with mixed stimulant- and hallucinogen-like effects. The aims of the present studies were to establish discrimination of S(+)-MDMA, R(-)-MDMA, or their combination as racemic MDMA in separate groups of mice to assess cross-substitution tests among all three compounds, to determine the time courses of the training doses, to assess...